Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Using biometric sensor data to monitor cancer patients during radiotherapy : Protocol for the OncoWatch feasibility study. / Holländer-Mieritz, Cecilie; Vogelius, Ivan R.; Kristensen, Claus A.; Green, Allan; Rindum, Judith L.; Pappot, Helle.

I: JMIR Research Protocols, Bind 10, Nr. 5, e26096, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Holländer-Mieritz, C, Vogelius, IR, Kristensen, CA, Green, A, Rindum, JL & Pappot, H 2021, 'Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study', JMIR Research Protocols, bind 10, nr. 5, e26096. https://doi.org/10.2196/26096

APA

Holländer-Mieritz, C., Vogelius, I. R., Kristensen, C. A., Green, A., Rindum, J. L., & Pappot, H. (2021). Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study. JMIR Research Protocols, 10(5), [e26096]. https://doi.org/10.2196/26096

Vancouver

Holländer-Mieritz C, Vogelius IR, Kristensen CA, Green A, Rindum JL, Pappot H. Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study. JMIR Research Protocols. 2021;10(5). e26096. https://doi.org/10.2196/26096

Author

Holländer-Mieritz, Cecilie ; Vogelius, Ivan R. ; Kristensen, Claus A. ; Green, Allan ; Rindum, Judith L. ; Pappot, Helle. / Using biometric sensor data to monitor cancer patients during radiotherapy : Protocol for the OncoWatch feasibility study. I: JMIR Research Protocols. 2021 ; Bind 10, Nr. 5.

Bibtex

@article{147af89bf3024ea6a8a70ee92f3be7a6,
title = "Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study",
abstract = "Background: Patients with head and neck cancer (HNC) experience severe side effects during radiotherapy (RT). Ongoing technological advances in wearable biometric sensors allow for the collection of objective data (eg, physical activity and heart rate), which might, in the future, help detect and counter side effects before they become severe. A smartwatch such as the Apple Watch allows for objective data monitoring outside the hospital with minimal effort from the patient. To determine whether such tools can be implemented in the oncological setting, feasibility studies are needed. Objective: This protocol describes the design of the OncoWatch 1.0 feasibility study that assesses the adherence of patients with HNC to an Apple Watch during RT. Methods: A prospective, single-cohort trial will be conducted at the Department of Oncology, Rigshospitalet (Copenhagen, Denmark). Patients aged ≥18 years intended for primary or postoperative curatively intended RT for HNC will be recruited. Consenting patients will be asked to wear an Apple Watch on the wrist during and until 2 weeks after RT. The study will include 10 patients. Data on adherence, data acquisition, and biometric data will be collected. Demographic data, objective toxicity scores, and hospitalizations will be documented. Results: The primary outcome is to determine if it is feasible for the patients to wear a smartwatch continuously (minimum 12 hours/day) during RT. Furthermore, we will explore how the heart rate and physical activity change over the treatment course. Conclusions: The study will assess the feasibility of using the Apple Watch for home monitoring of patients with HNC. Our findings may provide novel insights into the patient{\textquoteright}s activity levels and variations in heart rate during the treatment course. The knowledge obtained from this study will be essential for further investigating how biometric data can be used as part of symptom monitoring for patients with HNC.",
keywords = "Biometric sensor technology, Cancer, Head and neck cancer, Home monitoring, Patient-generated health data, Radiotherapy, Sensor, Smartwatch",
author = "Cecilie Holl{\"a}nder-Mieritz and Vogelius, {Ivan R.} and Kristensen, {Claus A.} and Allan Green and Rindum, {Judith L.} and Helle Pappot",
note = "Publisher Copyright: {\textcopyright} Cecilie Holl{\"a}nder-Mieritz, Ivan R Vogelius, Claus A Kristensen, Allan Green, Judith L Rindum, Helle Pappot.",
year = "2021",
doi = "10.2196/26096",
language = "English",
volume = "10",
journal = "J M I R Research Protocols",
issn = "1929-0748",
publisher = "J M I R Publications, Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Using biometric sensor data to monitor cancer patients during radiotherapy

T2 - Protocol for the OncoWatch feasibility study

AU - Holländer-Mieritz, Cecilie

AU - Vogelius, Ivan R.

AU - Kristensen, Claus A.

AU - Green, Allan

AU - Rindum, Judith L.

AU - Pappot, Helle

N1 - Publisher Copyright: © Cecilie Holländer-Mieritz, Ivan R Vogelius, Claus A Kristensen, Allan Green, Judith L Rindum, Helle Pappot.

PY - 2021

Y1 - 2021

N2 - Background: Patients with head and neck cancer (HNC) experience severe side effects during radiotherapy (RT). Ongoing technological advances in wearable biometric sensors allow for the collection of objective data (eg, physical activity and heart rate), which might, in the future, help detect and counter side effects before they become severe. A smartwatch such as the Apple Watch allows for objective data monitoring outside the hospital with minimal effort from the patient. To determine whether such tools can be implemented in the oncological setting, feasibility studies are needed. Objective: This protocol describes the design of the OncoWatch 1.0 feasibility study that assesses the adherence of patients with HNC to an Apple Watch during RT. Methods: A prospective, single-cohort trial will be conducted at the Department of Oncology, Rigshospitalet (Copenhagen, Denmark). Patients aged ≥18 years intended for primary or postoperative curatively intended RT for HNC will be recruited. Consenting patients will be asked to wear an Apple Watch on the wrist during and until 2 weeks after RT. The study will include 10 patients. Data on adherence, data acquisition, and biometric data will be collected. Demographic data, objective toxicity scores, and hospitalizations will be documented. Results: The primary outcome is to determine if it is feasible for the patients to wear a smartwatch continuously (minimum 12 hours/day) during RT. Furthermore, we will explore how the heart rate and physical activity change over the treatment course. Conclusions: The study will assess the feasibility of using the Apple Watch for home monitoring of patients with HNC. Our findings may provide novel insights into the patient’s activity levels and variations in heart rate during the treatment course. The knowledge obtained from this study will be essential for further investigating how biometric data can be used as part of symptom monitoring for patients with HNC.

AB - Background: Patients with head and neck cancer (HNC) experience severe side effects during radiotherapy (RT). Ongoing technological advances in wearable biometric sensors allow for the collection of objective data (eg, physical activity and heart rate), which might, in the future, help detect and counter side effects before they become severe. A smartwatch such as the Apple Watch allows for objective data monitoring outside the hospital with minimal effort from the patient. To determine whether such tools can be implemented in the oncological setting, feasibility studies are needed. Objective: This protocol describes the design of the OncoWatch 1.0 feasibility study that assesses the adherence of patients with HNC to an Apple Watch during RT. Methods: A prospective, single-cohort trial will be conducted at the Department of Oncology, Rigshospitalet (Copenhagen, Denmark). Patients aged ≥18 years intended for primary or postoperative curatively intended RT for HNC will be recruited. Consenting patients will be asked to wear an Apple Watch on the wrist during and until 2 weeks after RT. The study will include 10 patients. Data on adherence, data acquisition, and biometric data will be collected. Demographic data, objective toxicity scores, and hospitalizations will be documented. Results: The primary outcome is to determine if it is feasible for the patients to wear a smartwatch continuously (minimum 12 hours/day) during RT. Furthermore, we will explore how the heart rate and physical activity change over the treatment course. Conclusions: The study will assess the feasibility of using the Apple Watch for home monitoring of patients with HNC. Our findings may provide novel insights into the patient’s activity levels and variations in heart rate during the treatment course. The knowledge obtained from this study will be essential for further investigating how biometric data can be used as part of symptom monitoring for patients with HNC.

KW - Biometric sensor technology

KW - Cancer

KW - Head and neck cancer

KW - Home monitoring

KW - Patient-generated health data

KW - Radiotherapy

KW - Sensor

KW - Smartwatch

U2 - 10.2196/26096

DO - 10.2196/26096

M3 - Journal article

C2 - 33983123

AN - SCOPUS:85106248744

VL - 10

JO - J M I R Research Protocols

JF - J M I R Research Protocols

SN - 1929-0748

IS - 5

M1 - e26096

ER -

ID: 301695193